Capital Grand Est has announced additional funding for French medical device startup RDS, bringing its total seed capital to €13 million.
Once CE marking is obtained (anticipated by the end of 2023), the company plans to use these funds to advance towards the next phase in the creation of its MultiSense product, which includes market launch.
“We are very glad to welcome Capital Grand Est as an investor and, more broadly, for the support received during this seed stage. This investor backing confirms the appeal of our technology as we prepare for our Series A round,” said Elie Lobel, CEO of RDS. “A number of hospitals across Europe have also expressed their support, including in France, Belgium and Germany, a clear demonstration that our MultiSense device meets a real need in transforming patient care.”
“We are delighted to be supporting RDS on its journey, having followed this project closely for nearly three years. The recent developments, the forthcoming CE marking, and its complementary high-level team will help the company to grow rapidly to address an essential public health need: improving post-operative patient monitoring,” said Jean-François Rax, partner at Capital Grand Est. “I’m pleased to say we have already committed to supporting RDS as part of its Series A funding campaign.”
RDS creates MultiSense®, a next-generation Remote Patient Monitoring (RPM) system that includes a wearable patch track for capturing high-quality, real-time physiological information in a hospital or at home, as well as an online platform for healthcare professionals to interpret the data.
MultiSense has been validated in six clinical trials and is covered by more than 20 patents. Early 2024 is when marketing is anticipated to start in Europe.